Aimmune Therapeutics (NASDAQ:AIMT) has been assigned a $62.00 price objective by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 118.62% from the company’s current price.

AIMT has been the subject of several other reports. BidaskClub cut shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 11th. Roth Capital set a $80.00 price target on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 9th. Wedbush started coverage on shares of Aimmune Therapeutics in a report on Wednesday, October 17th. They set a “buy” rating and a $72.00 price target for the company. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 17th. Finally, Stifel Nicolaus started coverage on shares of Aimmune Therapeutics in a report on Thursday, September 13th. They set a “hold” rating and a $33.00 price target for the company. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Aimmune Therapeutics has an average rating of “Buy” and a consensus price target of $51.50.

NASDAQ AIMT opened at $28.36 on Monday. The stock has a market cap of $1.78 billion, a P/E ratio of -10.87 and a beta of -0.10. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.03. As a group, analysts predict that Aimmune Therapeutics will post -3.64 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. increased its holdings in Aimmune Therapeutics by 12.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 207,255 shares of the biotechnology company’s stock valued at $5,574,000 after buying an additional 23,678 shares in the last quarter. BlackRock Inc. increased its holdings in Aimmune Therapeutics by 18.4% in the second quarter. BlackRock Inc. now owns 3,643,840 shares of the biotechnology company’s stock valued at $97,984,000 after buying an additional 565,410 shares in the last quarter. Spark Investment Management LLC increased its holdings in Aimmune Therapeutics by 22.7% in the second quarter. Spark Investment Management LLC now owns 232,300 shares of the biotechnology company’s stock valued at $6,246,000 after buying an additional 43,000 shares in the last quarter. Northern Trust Corp increased its holdings in Aimmune Therapeutics by 26.3% in the second quarter. Northern Trust Corp now owns 518,581 shares of the biotechnology company’s stock valued at $13,945,000 after buying an additional 108,034 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Aimmune Therapeutics by 25.0% in the second quarter. Rhumbline Advisers now owns 41,731 shares of the biotechnology company’s stock valued at $1,122,000 after buying an additional 8,348 shares in the last quarter. 78.18% of the stock is owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: How to Use a Moving Average for TradingĀ 

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.